Invivo announces 13th Inspire Study enrollee — 4 takeaways

Adam Schrag -   Print  |

Cambridge, Mass.-based InVivo Therapeutics announced the newest patient enrollee into its Inspire Study at Camden, N.J.-based Cooper Neurological Institute.

Here are four things to know:


1. The Neuro-Spinal Scaffold Implant treats patients with complete (AIS A) traumatic acute spinal cord injury.


2. CNI spine program director Steven Yocom, DO, performed the procedure 29 hours after the injury occurred.


3. Dr. Yocom said, "We are excited to be part of the Inspire study and look forward to following the patient's progress."


4. Invivo CEO and Chairman Mark Perrin reported, "We now have 13 patients enrolled and in follow up, and we are pleased to have announced two enrollments in the last two weeks."


More articles on devices:
5 key thoughts on healthcare from Johnson & Johnson CEO Alex Gorsky

Mazor Robotics, Medtronic continue to push Mazor X commercialization: 5 things to know

Global hip replacement implant market to hit $9.1B by 2024; Zimmer Biomet leads space

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers